
Organic Process Research and Development p. 1227 - 1238 (2016)
Update date:2022-08-03
Topics:
Williams, Michael J.
Chen, Qinghao
Codan, Lorenzo
Dermenjian, Renee K.
Dreher, Spencer
Gibson, Andrew W.
He, Xianliang
Jin, Yan
Keen, Stephen P.
Lee, Alfred Y.
Lieberman, David R.
Lin, Wei
Liu, Guiquan
McLaughlin, Mark
Reibarkh, Mikhail
Scott, Jeremy P.
Strickfuss, Sophie
Tan, Lushi
Varsolona, Richard J.
Wen, Feng
We describe the route development and multikilogram-scale synthesis of an HCV NS5B site D inhibitor, MK-8876. The key topics covered are (1) process improvement of the two main fragments; (2) optimization of the initially troublesome penultimate step, a key bis(boronic acid) (BBA)-based borylation; (3) process development of the final Suzuki-Miyaura coupling; and (4) control of the drug substance form. These efforts culminated in a 28 kg delivery of the desired active pharmaceutical ingredient.
View MoreANHUI CHEM-BRIGHT BIOENGINEERING CO.,LTD
Contact:86-561-4080321
Address:No.8 Lieshan Industrial Zone of Huaibei
Contact:+86-575-82733999 0575-82732999
Address:hangzhou gulf fine chemical zone,shangyu city,zhejiang province
Contact:+36(21)2523420
Address:Head office: 1102 Budapest, SZENT LASZLO TER 24/B. 1/1., HUNGARY / CHINA
Shanghai Dano Pharmaceutical Co.,Ld.(expird)
Contact:+86-592-6266840
Address:Building 1 Room 512, 720 Cailun Rd, Zhangjiang High-Tech Park, Shanghai 201203, China
Chengdu Gelipu Biotechnology Co., Ltd.
website:http://www.glp-china.com
Contact:86-28-82610909
Address:chegndu
Doi:10.1016/0040-4039(94)02477-S
(1995)Doi:10.1038/nchem.2904
(2018)Doi:10.1021/jm050867d
(2006)Doi:10.1248/cpb.43.100
(1995)Doi:10.1021/op500222p
(2014)Doi:10.1016/j.bmcl.2014.07.019
(2014)